Guidelines

• An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations
• Belgian consensus guidelines for prostate core needle biopsy reporting
• PD-L1 Testing for Non-Small Cell Lung Cancer: Belgian Guidelines
• Prevention of chemotherapy-induced nausea and vomiting: Belgian antiemetic treatment options anno 2018
• The ION-Ghent guidelines for the management of immune related adverse events (irAE’s)
• The Belgian next generation sequencing guidelines for haematological and solid tumours
• Pathological diagnosis and molecular testing in non-small cell lung cancer: Belgian guidelines
• Adjuvant endocrine therapy in preand perimenopausal women with breast cancer: practice guidelines
• Molecular diagnostics on tissue samples obtained through EBUSTBNA: review on practice guidelines
• RAS-testing in colorectal cancer: Belgian guidelines
• Early detection of prostate cancer: the EAU versus the AUA recommendation
• Penile cancer practice guidelines
• Update of the Belgian guidelines for HER2 testing in breast cancer
• Belgian Society of Medical Oncology (BSMO) task force on breast cancer survivorship
• Soft tissue sarcoma: the clinically relevant basics and an update on systemic therapy options for patients with advanced disease
• Practical guidelines in the management of uveal melanoma
• Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy
• Belgian guidelines for HER2 testing in gastric cancer
• Belgian consensus guidelines for the subtyping of NSCLC
• Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapyinduced anemia
• Belgian guidelines for HER2/neu testing in breast cancer